Busulfan-fludarabine-clofarabine with allogeneic stem cell transplantation for advanced refractory acute myeloid leukemia, myelodysplastic syndrome and advanced, imatinib-efractory chronic myeloid leukemia. A randomized phase II study.

Trial Profile

Busulfan-fludarabine-clofarabine with allogeneic stem cell transplantation for advanced refractory acute myeloid leukemia, myelodysplastic syndrome and advanced, imatinib-efractory chronic myeloid leukemia. A randomized phase II study.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2013

At a glance

  • Drugs Busulfan (Primary) ; Clofarabine (Primary) ; Fludarabine (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Sep 2012 Planned end date changed from 1 Sep 2012 to 1 Sep 2014 as reported by ClinicalTrials.gov.
    • 01 Jun 2011 Results published in Biology of Blood and Marrow Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top